MI great analyses. Thanks for your efforts to breakdown all that information. Great summary of the delisting pathway...provides a lot of clarity on the matter.
To the group collectively, some thoughts about the Ferring Takeda deal. Four days ago, Apricus provided a corporate update on their website. There was no mention that Takeda had been replaced by Ferring to market in the UK. In fact, they still included Takeda in the corporate update as being one of their marketing partners...not a fan of the lack of transparency. I understand the notion that it's better to get somebody in place to market Vitaros if another company is not doing it to our company's satisfaction, but giving up milestone payments (even if on paper) and taking lower tired royalties, does not feel like winning to me. Sure if no volume in sales was being generated, going another direction could in theory be the better move, but our first to market Vitaros partner is saying no thanks. I have always had one major concern with Vitaros, and that is this question, "is it effective?" Logic seems to dictate that if it is, it should fly off the shelves, if it's not, then it will start to present itself...
I've seen the articles related to it's efficacy and something is not stacking up here...
Either way, it doesn't make sense that I get out of APRI now...I can only hold on and hope that our management executes and that are product works. |
